AstraZeneca gets marketing permission for cancer drug in India

New Delhi: AstraZeneca Pharma India on Thursday said it has received approval from the Indian drug regulator to market Durvalumab, a cancer treatment medicine, in the country.

The company has received import and market permission for Durvalumab from the Drug Controller General of India (DCGI), AstraZeneca Pharma India said in a statement.

The approval paves the way for the company to launch the product in the country, it added.

Durvalumab is indicated as a treatment option for patients with locally advanced, unresectable non-small cell lung Cancer (NSCLC) and metastatic urothelial carcinoma.

“The import and market permission for Durvalumab for unresectable stage III Non-Small Cell Lung Cancer (NSCLC) and locally advanced or metastatic urothelial carcinoma is a significant milestone for patients who have currently limited treatment options,” AstraZeneca Pharma India Managing Director Gagan Singh said.

In India, around one third of patients with NSCLC are present with stage III disease and the company is happy to bring the first immunotherapy into this setting for patients, he added.

  • Related Posts

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    New Delhi:  Aurobindo Pharma Ltd on Tuesday said it has set April 23 as the opening date for its Rs 800 crore buyback offer. The closing date for the buyback…

    Boehringer Ingelheim launches AI centre for pharma research in London

    Bengaluru: German drugmaker Boehringer Ingelheim is launching a ​centre for artificial ​intelligence and machine learning in London, it said ​on Monday, as it seeks to expand its AI capabilities in…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Boehringer Ingelheim launches AI centre for pharma research in London

    Boehringer Ingelheim launches AI centre for pharma research in London

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid